EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 170 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $270,161 | -19.0% | 17,132 | -0.2% | 0.00% | – |
| Q2 2023 | $333,648 | +37013.2% | 17,163 | -45.8% | 0.00% | -100.0% |
| Q1 2023 | $899 | +2.0% | 31,688 | +5.2% | 0.00% | 0.0% |
| Q4 2022 | $881 | -99.9% | 30,127 | -2.3% | 0.00% | 0.0% |
| Q3 2022 | $815,000 | -40.4% | 30,851 | +0.2% | 0.00% | -50.0% |
| Q2 2022 | $1,368,000 | -16.3% | 30,782 | -6.8% | 0.00% | 0.0% |
| Q1 2022 | $1,635,000 | -0.1% | 33,027 | +2.8% | 0.00% | 0.0% |
| Q4 2021 | $1,637,000 | -11.4% | 32,142 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $1,847,000 | +15.4% | 33,111 | -11.4% | 0.00% | 0.0% |
| Q2 2021 | $1,600,000 | +5.2% | 37,381 | +2.6% | 0.00% | 0.0% |
| Q1 2021 | $1,521,000 | -6.7% | 36,448 | +4.1% | 0.00% | 0.0% |
| Q4 2020 | $1,631,000 | +10.0% | 35,026 | +0.4% | 0.00% | 0.0% |
| Q3 2020 | $1,483,000 | -10.1% | 34,901 | +1.5% | 0.00% | -33.3% |
| Q2 2020 | $1,650,000 | +1.3% | 34,395 | -2.9% | 0.00% | 0.0% |
| Q1 2020 | $1,629,000 | -19.8% | 35,405 | +4.7% | 0.00% | 0.0% |
| Q4 2019 | $2,031,000 | +11.2% | 33,803 | +4.7% | 0.00% | 0.0% |
| Q3 2019 | $1,826,000 | -1.4% | 32,287 | -2.9% | 0.00% | 0.0% |
| Q2 2019 | $1,851,000 | +14.6% | 33,241 | +3.9% | 0.00% | 0.0% |
| Q1 2019 | $1,615,000 | +17.5% | 31,980 | -6.2% | 0.00% | 0.0% |
| Q4 2018 | $1,374,000 | -25.1% | 34,105 | +28.9% | 0.00% | -25.0% |
| Q3 2018 | $1,835,000 | -0.7% | 26,468 | +8.4% | 0.00% | 0.0% |
| Q2 2018 | $1,848,000 | +76.0% | 24,427 | +22.6% | 0.00% | +100.0% |
| Q1 2018 | $1,050,000 | +0.8% | 19,929 | +2.2% | 0.00% | 0.0% |
| Q4 2017 | $1,042,000 | +2.4% | 19,501 | +14.2% | 0.00% | 0.0% |
| Q3 2017 | $1,018,000 | -19.3% | 17,076 | +6.8% | 0.00% | -33.3% |
| Q2 2017 | $1,262,000 | -10.9% | 15,996 | -6.4% | 0.00% | 0.0% |
| Q1 2017 | $1,417,000 | +43.6% | 17,088 | +37.4% | 0.00% | 0.0% |
| Q4 2016 | $987,000 | +20.4% | 12,440 | +6.2% | 0.00% | +50.0% |
| Q3 2016 | $820,000 | +127.1% | 11,713 | +26.0% | 0.00% | +100.0% |
| Q2 2016 | $361,000 | -0.8% | 9,295 | +3.3% | 0.00% | 0.0% |
| Q1 2016 | $364,000 | -54.5% | 8,998 | -0.2% | 0.00% | -66.7% |
| Q4 2015 | $800,000 | +36.3% | 9,018 | +13.8% | 0.00% | +50.0% |
| Q3 2015 | $587,000 | -3.9% | 7,923 | +4.9% | 0.00% | 0.0% |
| Q2 2015 | $611,000 | – | 7,555 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |